Skip to content
← Full study record

NCT00387348 · OUTCOME

Depression Response Rate of Escitalopram Oxalate 10 mg Once Daily Compared to Placebo Once Daily for Major Depressive Disorder

Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer · Source last updated 2012-12-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
number of participants with response
Interval / dispersion
Not reported
Time frame
4 weeks

What was measured

Response rate was defined as a 50% reduction in the Hamilton Depression Rating Scale (HAM-D) scores over 4 weeks. The HAM-D can have total scores that range from 0 to 50, with higher scores indicating greater depression. Scores over 14 are considered to be in the depressed range.

Analysis population: The efficacy analysis was intent to treat and all randomized participants were analyzed

Groups in this outcome

Placebo-Placebo

Participants in this arm were randomized to receive placebo once daily by mouth for the first 4 weeks and placebo oncedaily by mouth for the second 4 weeks

Placebo-Escitalopram

Participants in this arm were randomized to receive placebo once daily by mouth for the first 4 weeks and escitalopram 10 mg once daily by mouth for the second 4 weeks

Escitalopram-Placebo

Participants in this arm were randomzied to receive escitalopram f10 mg once daily by mouth or the first 4 weeks and placebo once daily by mouth for the second 4 weeks

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Placebo-Placebo8
Placebo-Escitalopram5
Escitalopram-Placebo11

Reported measurements

Source class 1
Values in number of participants with response · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Placebo-Placebo30.52Not reportedNot reportedNot reported
Placebo-Escitalopram10.47Not reportedNot reportedNot reported
Escitalopram-Placebo60.52Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.52
        value
        3
      2. group Id
        OG001
        spread
        0.47
        value
        1
      3. group Id
        OG002
        spread
        0.52
        value
        6
denoms
  1. counts
    1. group Id
      OG000
      value
      8
    2. group Id
      OG001
      value
      5
    3. group Id
      OG002
      value
      11
    units
    Participants
description
Response rate was defined as a 50% reduction in the Hamilton Depression Rating Scale (HAM-D) scores over 4 weeks. The HAM-D can have total scores that range from 0 to 50, with higher scores indicating greater depression. Scores over 14 are considered to be in the depressed range.
groups
  1. description
    Participants in this arm were randomized to receive placebo once daily by mouth for the first 4 weeks and placebo oncedaily by mouth for the second 4 weeks
    id
    OG000
    title
    Placebo-Placebo
  2. description
    Participants in this arm were randomized to receive placebo once daily by mouth for the first 4 weeks and escitalopram 10 mg once daily by mouth for the second 4 weeks
    id
    OG001
    title
    Placebo-Escitalopram
  3. description
    Participants in this arm were randomzied to receive escitalopram f10 mg once daily by mouth or the first 4 weeks and placebo once daily by mouth for the second 4 weeks
    id
    OG002
    title
    Escitalopram-Placebo
param Type
NUMBER
population Description
The efficacy analysis was intent to treat and all randomized participants were analyzed
reporting Status
POSTED
time Frame
4 weeks
title
Depression Response Rate of Escitalopram Oxalate 10 mg Once Daily Compared to Placebo Once Daily for Major Depressive Disorder
type
PRIMARY
unit Of Measure
number of participants with response

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice